Promising biomarkers for predicting the outcomes of patients withKRASwild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis

Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification byKRASMutations in Advanced Colorectal Cancer

(2013) Issa J. Dahabreh et al.   ANNALS OF INTERNAL MEDICINE

PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

(2012) Arjun Sood et al.   Clinical Colorectal Cancer

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

(2012) Carsten Bokemeyer et al.   EUROPEAN JOURNAL OF CANCER

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

(2012) Zu-Yao Yang et al.   Journal of Hematology & Oncology

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer

(2011) Jin Hyun Park et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?

(2011) Alessandro Inno et al.   Clinical Colorectal Cancer

The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial

(2011) D.P. Modest et al.   INTERNATIONAL JOURNAL OF CANCER

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy

(2011) Jen-Kou Lin et al.   JOURNAL OF SURGICAL ONCOLOGY

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients

(2011) Zacharenia Saridaki et al.   PLoS One

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

(2010) F Di Fiore et al.   BRITISH JOURNAL OF CANCER

Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review

(2010) Jolien Tol et al.   CLINICAL THERAPEUTICS

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

(2010) Jolien Tol et al.   EUROPEAN JOURNAL OF CANCER

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer

(2010) Geraldine Perkins et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

(2010) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

(2010) Andrea Sartore-Bianchi et al.   Targeted Oncology

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

(2009) F Loupakis et al.   BRITISH JOURNAL OF CANCER

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

(2009) Andrea Sartore-Bianchi et al.   PLoS One

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

(2008) Alberto F. Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Helical domain and kinase domain mutations in p110  of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

(2008) L. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA